Michael A. Mcmanus Jr. - 25 Jun 2021 Form 4/A - Amendment Insider Report for NOVAVAX INC (NVAX)

Role
Director
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
25 Jun 2021
Net transactions value
$0
Form type
4/A - Amendment
Filing time
20 Aug 2021, 17:30:38 UTC
Date Of Original Report
29 Jun 2021
Previous filing
21 Jun 2021
Next filing
20 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +3,450 +58% 9,401 25 Jun 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -3,450 -50% $0.000000 3,450 25 Jun 2021 Common Stock 3,450 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment to the original Form 4 filed on June 29, 2021 is being filed to correct the number of restricted stock units ("RSUs") vested on June 25, 2021.
F2 Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F3 One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 25, 2020 grant date subject to continued service on the Company's Board of Directors through the vesting date.